ArticleWorld journal of clinical oncology2022
Epstein-Barr virus-associated smooth muscle tumors in immunocompromised patients: Six case reports.
Article in World journal of clinical oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 12 citations in OpenAlex.
- Epstein-Barr virus-associated smooth muscle tumor of the liver after umbilical cord blood transplantation for acute myeloid leukemia.Clinical journal of gastroenterology · 2026Article
- Endobronchial Epstein-Barr Virus-Associated Smooth Muscle Tumor in Advanced HIV Infection: A Rare Case.The American journal of case reports · 2026Article
- Solitary thoracic Epstein-Barr virus-associated smooth muscle tumor presenting after kidney transplant: illustrative case.Journal of neurosurgery. Case lessons · 2026Article
- A System-Level Perspective on Epstein-Barr Virus Persistence: The Partial Lytic Reactivation.International journal of molecular sciences · 2026Review
- Epstein-Barr virus-associated smooth muscle tumor of the lung in a child: a case report and literature review.Frontiers in medicine · 2026Article
- Hepatic Epstein-Barr Virus-Associated Smooth Muscle Tumor in a Young Woman With Congenital HIV.Cureus · 2025Article
- Pediatric Liver Transplant Complications: EBV-Associated Tumors and Infection Management Strategies.The American journal of case reports · 2025Article
- Test yourself answer: a young male with right shoulder pain.Skeletal radiology · 2025Article
- Pictorial essay on selected new, emerging, and reclassified entities in the 2020 WHO classification of soft tissue tumors.European journal of radiology · 2025Review
- Imaging of cystic fibrosis manifestations in the abdomen.Abdominal radiology (New York) · 2025Review
- A Clinicopathology Review and Update of Epstein-Barr Virus-Associated Mesenchymal Tumors.Cancers · 2023Review
- Clinical Course of a Rare Epstein-Barr Virus-Associated Smooth Muscle Tumor and Its Genomic Analysis.Case reports in oncologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEpstein-Barr virus associated smooth muscle tumor (EBV-SMT) is a rare oncological entity. However, there is an increasing incidence of EBV-SMTs, as the frequency of organ transplantation and immunosuppression grows. EBV-SMT diagnosis relies on histopathology and immunochemical staining to distinguish it from post-transplant lymphoproliferative disorder (PTLD). There is no clear consensus on the treatment of EBV-SMTs. However, surgical resection, chemotherapy, radiation therapy, and immunosuppression reduction have been explored with varying degrees of success. CASE SUMMARY: Our case series includes six cases of EBV-SMTs across different age groups, with different treatment modalities, adding to the limited existing literature on this rare tumor. The median latency time between immunosuppression and disease diagnosis is four years. EBV-SMTs present with variable degrees of aggressiveness and seem to have worse clinical outcomes in patients with tumor multiplicity and worse immunocompetency.
conclusionIt is imperative to continue building on this knowledge and keeping EBV-SMTs on the differential in immunocompromised individuals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.